23 results
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
5 Aug 20
Verrica Pharmaceuticals Reports Second Quarter 2020 Financial Results
7:28am
the third quarter of 2020 to discuss next steps for resubmission of an NDA for VP-102 following Complete Response Letter -
- Key leadership additions … any clinical safety or efficacy questions, and having recently strengthened leadership in clinical, CMC, and regulatory affairs, we intend to request
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
23 Jul 20
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes
7:45am
Exhibit 99.1
Verrica Pharmaceuticals Announces Clinical and Drug Development Leadership Changes
– Dr. Gary Goldenberg appointed Chief Medical … Officer;
Dr. Brad Catalone assumes the role of Head of Drug Development –
– New leadership strengthens expertise in Clinical, Chemistry, Manufacturing
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
6 Nov 19
Verrica Pharmaceuticals Reports Third Quarter 2019 Financial Results
4:18pm
analyses of pooled results of the Phase 3 CAMP studies in molluscum, and the Phase 2COVE-1 study in common warts
-Strengthened leadership … study, and was well-tolerated with a low rate of adverse events across all studies.
Continued to advance Company leadership and commercialization
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
7 Mar 19
Verrica Reports Fourth Quarter and Full Year 2018 Financial Results
4:16pm
for the same period in 2017. The increase was primarily due to the expansion of the executive leadership team, increased corporate infrastructure … to the expansion of the executive leadership team, increased corporate infrastructure, and additional costs associated with operating as a public company
8-K
EX-99.1
VRCA
Verrica Pharmaceuticals Inc
13 Mar 20
Verrica Pharmaceuticals Reports Fourth Quarter and Full-Year 2019 Financial Results
4:05pm
of July 13, 2020. We also added to the body of clinical evidence supportingVP-102, and bolstered our leadership team, further readying the organization … the second quarter of 2021.
Significantly strengthened the organization’s leadership, and further enhanced its manufacturing and commercial
8-K
EX-99.1
tizgo
10 Jun 20
Verrica Pharmaceuticals Appoints Diem Nguyen, Ph.D., M.B.A., to its Board of Directors
7:41am
8-K
EX-99.1
zqqnw j7xl6u5t5i
7 Nov 18
Verrica Pharmaceuticals Reports Third Quarter 2018 Financial Results
4:44pm
8-K
EX-99.1
xv6zuu1ogdjm spnw
7 Aug 18
Verrica Reports Second Quarter 2018 Financial Results
4:07pm
8-K
EX-99.1
91vbxscq7ra1tq2s
8 Sep 20
Regulation FD Disclosure
7:01am
8-K
EX-99.1
2cfi 2wig
6 Jan 21
Regulation FD Disclosure
6:05am
8-K
EX-99.1
jfe0gtsj lni67sj0t6
10 Aug 21
Verrica Pharmaceuticals Reports Second Quarter 2021 Financial Results
8:01am
8-K
EX-99.2
stmmpzaz hq66f8
10 Nov 20
Regulation FD Disclosure
7:52am
CORRESP
auu09
29 May 18
Correspondence with SEC
12:00am
DEF 14A
yofkhtn ju4p24eg2i
25 Apr 19
Definitive proxy
8:51am
DRS/A
a5h5quvv9 uc3
2 May 18
Draft registration statement (amended)
12:00am
S-1/A
n95se7miq4
5 Jun 18
IPO registration (amended)
12:00am